397 related articles for article (PubMed ID: 12417568)
1. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
Rauch F; Travers R; Plotkin H; Glorieux FH
J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568
[TBL] [Abstract][Full Text] [Related]
2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
3. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
[TBL] [Abstract][Full Text] [Related]
5. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
6. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
Rauch F; Plotkin H; Zeitlin L; Glorieux FH
J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
[TBL] [Abstract][Full Text] [Related]
7. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
8. Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux FH
Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
10. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
Rauch F; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
[TBL] [Abstract][Full Text] [Related]
11. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
[TBL] [Abstract][Full Text] [Related]
12. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
13. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
Gökşen D; Coker M; Darcan S; Köse T; Kara S
Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
[TBL] [Abstract][Full Text] [Related]
14. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
15. Two doses of pamidronate in infants with osteogenesis imperfecta.
Senthilnathan S; Walker E; Bishop NJ
Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
[TBL] [Abstract][Full Text] [Related]
16. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
Land C; Rauch F; Glorieux FH
J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
18. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.
Rauch F; Lalic L; Roughley P; Glorieux FH
J Bone Miner Res; 2010 Jun; 25(6):1367-74. PubMed ID: 19929435
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
[TBL] [Abstract][Full Text] [Related]
20. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
[No Abstract] [Full Text] [Related]
[Next] [New Search]